This page compares Mounjaro (tirzepatide) and Ozempic (semaglutide) specifically for weight loss outcomes. Both are injectable medications used in obesity and diabetes management, but they work differently. Understanding those differences — in mechanism, clinical data, cost, and access — helps patients have more informed conversations with their prescribers.
At a Glance
| Criterion | Mounjaro (tirzepatide) | Ozempic (semaglutide) |
|---|---|---|
| Active Ingredient | Tirzepatide | Semaglutide |
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| FDA Approval | Type 2 diabetes (2022); obesity as Zepbound (2023) | Type 2 diabetes (2017); obesity as Wegovy (2021) |
| Avg. Weight Loss (trials) | ~15–22% body weight (SURMOUNT trials) | ~10–15% body weight (STEP trials) |
| Dosing | Once weekly injection; 2.5–15 mg | Once weekly injection; 0.25–2 mg |
| List Price (monthly) | ~$1,000–$1,100 (Mounjaro); ~$1,060 (Zepbound) | ~$935–$1,000 (Ozempic); ~$1,350 (Wegovy) |
| Availability | Widely available; some supply variability | Widely available; periodic shortages reported |
| Best For | T2D with higher weight-loss goals; those needing dual-hormone action | T2D or obesity; cardiovascular risk reduction; longer track record |
Active Ingredient & Mechanism
Ozempic contains semaglutide, a GLP-1 receptor agonist that mimics the glucagon-like peptide-1 hormone. It slows gastric emptying, reduces appetite, and stimulates insulin release in a glucose-dependent manner. Mounjaro contains tirzepatide, which is a dual agonist — it activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. The addition of GIP receptor activity is believed to contribute to greater reductions in appetite and fat mass, though the precise additive effect is still being studied.
This mechanistic difference is central to understanding why clinical trial outcomes differ between the two drugs. It does not, however, mean one is universally superior for every individual — response to each medication can vary based on genetics, metabolic health, and tolerability.
FDA Approval & Intended Use
Semaglutide (Ozempic) received FDA approval for type 2 diabetes management in 2017, giving it a longer real-world safety record. Its obesity-specific formulation, Wegovy, was approved in 2021. Tirzepatide (Mounjaro) was approved for type 2 diabetes in 2022, and its obesity-specific brand, Zepbound, received FDA approval in late 2023. Both drugs are sometimes prescribed off-label — for example, Mounjaro may be prescribed off-label for weight loss where insurance covers diabetes indications, and Ozempic is frequently used off-label for weight management.
It is worth noting that Ozempic has demonstrated cardiovascular outcome benefits in trials such as LEADER and SUSTAIN-6, and the SELECT trial (2023) showed semaglutide reduced major cardiovascular events in people with obesity but without diabetes. Mounjaro's cardiovascular outcomes data is emerging, with the SURPASS-CVOT trial underway.
Weight Loss Clinical Data
Head-to-head clinical trials between tirzepatide and semaglutide for weight loss are limited, but existing data provides meaningful context. In the SURMOUNT-1 trial, participants taking tirzepatide 15 mg lost an average of approximately 22.5% of body weight over 72 weeks. The STEP 1 trial for semaglutide 2.4 mg (Wegovy dose) showed an average loss of approximately 14.9% body weight over 68 weeks. A 2023 network meta-analysis and the SURMOUNT-5 trial — which directly compared tirzepatide to semaglutide 2.4 mg — found tirzepatide produced statistically greater weight loss on average.
However, these are averages across large populations. Individual results vary considerably. Some patients respond strongly to semaglutide and minimally to tirzepatide, and vice versa. Both drugs significantly outperform placebo, and both are considered highly effective compared to older weight-loss medications.
Dosing & Administration
Both medications are administered as once-weekly subcutaneous injections and come in pre-filled auto-injector pens. Mounjaro starts at 2.5 mg weekly and can be titrated up to 15 mg in 2.5 mg increments, typically every four weeks. Ozempic starts at 0.25 mg weekly for the first four weeks, then 0.5 mg, with a maximum dose of 2 mg for diabetes; Wegovy reaches a maximum of 2.4 mg for obesity management. Titration schedules are designed to minimize gastrointestinal side effects during dose escalation for both drugs.
Cost & Insurance Coverage
List prices for both medications are high, typically ranging from approximately $900 to $1,350 per month without insurance. Mounjaro and Zepbound are manufactured by Eli Lilly; Ozempic and Wegovy are manufactured by Novo Nordisk. Savings cards and manufacturer coupons can reduce out-of-pocket costs significantly for commercially insured patients — Eli Lilly has offered Mounjaro for as low as $25/month with eligible insurance, and Novo Nordisk has similar programs. Medicare and Medicaid coverage for obesity-specific indications has historically been limited, though policy is evolving.
Compounded versions of both semaglutide and tirzepatide became widely available during shortage periods, though the FDA has raised safety concerns about compounded formulations and their regulatory status is subject to change as supply normalizes.
Side Effects & Tolerability
The side effect profiles of Mounjaro and Ozempic are broadly similar, reflecting their shared GLP-1 mechanism. The most commonly reported effects include nausea, vomiting, diarrhea, constipation, and reduced appetite. These are typically most pronounced during dose titration and tend to subside over time. Both drugs carry a boxed warning regarding the risk of thyroid C-cell tumors observed in rodent studies, though this has not been confirmed in humans. Pancreatitis, gallbladder disease, and acute kidney injury are listed as potential risks for both.
Some reports suggest gastrointestinal side effects may be somewhat more pronounced with tirzepatide at higher doses, though clinical trial dropout rates due to adverse events were comparable. Neither drug should be used during pregnancy, and both require caution in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Availability
Both Mounjaro and Ozempic have experienced supply shortages due to high demand since 2022. As of 2024 and into 2025, availability has generally improved for both, though regional pharmacy shortages can still occur. Zepbound (tirzepatide for obesity) and Wegovy (semaglutide for obesity) may have different pharmacy availability compared to their diabetes-branded counterparts. Patients and prescribers often need to check multiple pharmacies or use specialty mail-order pharmacies. Telehealth platforms have become a common access point for both medications.
Key Takeaway
The core difference between Mounjaro and Ozempic for weight loss lies in their mechanisms and average clinical outcomes: tirzepatide's dual GIP/GLP-1 action is associated with greater average weight loss in trials, while semaglutide has a longer approval history, established cardiovascular outcome data, and a broader base of real-world evidence. Cost, insurance coverage, individual tolerability, and a prescriber's clinical judgment all play significant roles in determining which medication a given patient uses.